PTCT Healthcare

PTC Therapeutics, Inc.

$68.12+11.89%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 5.7B USD
Enterprise value: 3.3B USD
Full-time employees: 991

Overall health

Strength: more profitable than most peersmore profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: higher risk than most peers on debt, liquidity or share-price swings
About average: valuation

Ranks #857 of 1,157 healthcare companies (bottom 27%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
PTC Therapeutics's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Shareholders being diluted. Shares outstanding up 14% from December 2022 to July 2026.
PTC Therapeutics had 14% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.PTC Therapeutics had 14% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Earnings slid into a loss. Loss per share this year after a profit last year.
PTC Therapeutics made a loss per share in its latest year after a profit the year before.
Valuation signals disagree. Cheaper than 55% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 55% of peers on operating cash profit, but only 0% on earnings.
Relative to its operating cash profit (EBITDA), PTC Therapeutics looks cheaper than 55% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, PTC Therapeutics looks cheaper than 55% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

StockQuotient Score

38/ 100

Oct 5 37 → Nov 4 38 (+1)

Valuation

Is the price right?

44/100

Moderate▼ 1 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Share count up 906.2% (existing holders diluted)

Valuation also moves with the share price every day.

Why it changed since the Oct 27, 2026 close: Score 45 → 44

Share price +9.7%-1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Held back by:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-0.7%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield4.8%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score 0.21Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-0.7%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield-2.9%

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

9/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 22.0%

Why

Weaker than most peers on:

▼ Revenue growth
▼ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a profit to a loss33% base weight · Z-score -1.99Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth7.2%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 0.16Sector median: 0.0584 · MAD: 0.0840

Revenue growth-42.8%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -4.87Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

86/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 19.5 points to 12.5%

Why

Stronger than most peers on:

▲ ROIC
▲ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin12.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.44Sector median: 0.0706 · MAD: 0.1217

Return on assets-1.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.53Sector median: 0.0166 · MAD: 0.0537

Return on invested capital52.8%

Yahoo Finance fallback · SEC operating income or invested capital unavailable · trailing 12 monthsOutlier capped at sector 5th/95th percentile33% base weight · Z-score 3.81Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin50.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equityUnavailable

Missing · left out of the scoreInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.55

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.24Sector median: 0.6250 · MAD: 0.3380

Current ratio3.39×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.58Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about PTC Therapeutics

Is PTC Therapeutics getting weaker?: Its latest SEC filing (Jul 30, 2026) was mixed: some things better, some worse: operating margin rose 19.5 points to 12.5%; share count up 906.2%. Its overall score is unchanged at 38/100 since Oct 28, 2026.
How is PTC Therapeutics valued vs its peers?: Priced about in line with its peers. Valuation scores 44/100 against 1,393 healthcare peers. Earnings yield -0.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -0.7% vs peers 1.5% (weaker than 100% of peers).
Is PTC Therapeutics growing?: More slowly than most of its peers. Growth scores 9/100 against 1,393 healthcare peers. Revenue growth -42.8% vs a peer median of 6.1% (weaker than 100% of peers).Revenue growth -42.8% vs peers 6.1% (weaker than 100% of peers).
How profitable is PTC Therapeutics?: More profitable than most of its peers. Profitability scores 86/100 against 1,393 healthcare peers. Return on invested capital 52.8% vs a peer median of 4.7% (stronger than 95% of peers).Return on invested capital 52.8% vs peers 4.7% (stronger than 95% of peers). Return on assets -1.2% vs a peer median of 1.7% (weaker than 63% of peers).Return on assets -1.2% vs peers 1.7% (weaker than 63% of peers).
How risky is PTC Therapeutics?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Jul 30, 2026 · compared with the quarter ended Mar 31, 2026

Mixed: some things better, some worse

Operating margin rose 19.5 points to 12.5%
Share count up 906.2% (existing holders diluted)

	Previous quarter	Latest quarter	Change
Revenue (12 months)	827.1M USD	1.0B USD	+22.0%
Net income (12 months)	−186.4M USD	−38.0M USD	−79.6%
Operating margin	-7.1%	12.5%	+19.5 pts
Free cash flow (12 months)	−226.3M USD	−39.8M USD	−82.4%
Cash	834.0M USD	1.0B USD	+25.9%
Shares outstanding	8.3M	83.5M	+906.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	-69.5%	-64.0%	-46.9%	-37.5%	50.1%	▲ 88 pts
Net margin	-97.3%	-80.0%	-66.8%	-45.0%	39.4%	▲ 84 pts
Return on assets (ROA)	-27.0%	-32.8%	-33.1%	-21.3%	23.5%	▲ 45 pts
Return on equity (ROE)	—	—	—	—	—	—
Free cash flow margin	-51.9%	-55.6%	-19.9%	-14.2%	40.6%	▲ 55 pts
Current ratio	1.87×	1.71×	2.02×	2.35×	2.35×	▼ 0.1%
Quick ratio	1.84×	1.65×	1.97×	2.31×	2.27×	▼ 1.9%
Debt to equity	—	—	—	—	—	—

PTCT price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: more profitable than most peersmore profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: higher risk than most peers on debt, liquidity or share-price swings

About average: valuation

Ranks #857 of 1,157 healthcare companies (bottom 27%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.

PTC Therapeutics's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.

Shareholders being diluted. Shares outstanding up 14% from December 2022 to July 2026.

PTC Therapeutics had 14% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.PTC Therapeutics had 14% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Earnings slid into a loss. Loss per share this year after a profit last year.

PTC Therapeutics made a loss per share in its latest year after a profit the year before.

Valuation signals disagree. Cheaper than 55% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 55% of peers on operating cash profit, but only 0% on earnings.

Relative to its operating cash profit (EBITDA), PTC Therapeutics looks cheaper than 55% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, PTC Therapeutics looks cheaper than 55% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Questions investors ask about PTC Therapeutics

Is PTC Therapeutics getting weaker?

Its latest SEC filing (Jul 30, 2026) was mixed: some things better, some worse: operating margin rose 19.5 points to 12.5%; share count up 906.2%. Its overall score is unchanged at 38/100 since Oct 28, 2026.

How is PTC Therapeutics valued vs its peers?

Priced about in line with its peers. Valuation scores 44/100 against 1,393 healthcare peers. Earnings yield -0.7% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -0.7% vs peers 1.5% (weaker than 100% of peers).

Is PTC Therapeutics growing?

More slowly than most of its peers. Growth scores 9/100 against 1,393 healthcare peers. Revenue growth -42.8% vs a peer median of 6.1% (weaker than 100% of peers).Revenue growth -42.8% vs peers 6.1% (weaker than 100% of peers).

How profitable is PTC Therapeutics?

More profitable than most of its peers. Profitability scores 86/100 against 1,393 healthcare peers. Return on invested capital 52.8% vs a peer median of 4.7% (stronger than 95% of peers).Return on invested capital 52.8% vs peers 4.7% (stronger than 95% of peers). Return on assets -1.2% vs a peer median of 1.7% (weaker than 63% of peers).Return on assets -1.2% vs peers 1.7% (weaker than 63% of peers).

How risky is PTC Therapeutics?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

827.1M USD

1.0B USD

+22.0%

Net income (12 months)

−186.4M USD

−38.0M USD

−79.6%

Operating margin

-7.1%

12.5%

+19.5 pts

Free cash flow (12 months)

−226.3M USD

−39.8M USD

−82.4%

Cash

834.0M USD

1.0B USD

+25.9%

Shares outstanding

8.3M

83.5M

+906.2%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

-69.5%

-64.0%

-46.9%

-37.5%

50.1%

▲ 88 pts

Net margin

-97.3%

-80.0%

-66.8%

-45.0%

39.4%

▲ 84 pts

Return on assets (ROA)

-27.0%

-32.8%

-33.1%

-21.3%

23.5%

▲ 45 pts

Return on equity (ROE)

—

Free cash flow margin

-51.9%

-55.6%

-19.9%

-14.2%

40.6%

▲ 55 pts

Current ratio

1.87×

1.71×

2.02×

2.35×

▼ 0.1%

Quick ratio

1.84×

1.65×

1.97×

2.31×

2.27×

▼ 1.9%

Debt to equity

—